HedgeCo.Net — Apollo Global Management is in talks to acquire Johnson & Johnson’s DePuy Synthes orthopedics unit at a valuation close to $20 billion, according to people familiar with the matter cited by Bloomberg on September 11 and independently carried by Reuters and The Wall Street Journal. Coverage framed the discussions as live but unfinished: an agreement could come within weeks, or talks could end without a deal, another bidder could emerge, or J&J could still spin DePuy Synthes as a public company.
DePuy Synthes makes devices used in hip, knee, and related orthopedic procedures and generated about $9.3 billion in 2025 sales, per the same reporting. J&J said last year it planned to separate the unit into a standalone company within roughly 18 to 24 months as it sharpens focus on higher-growth areas; Bloomberg noted several private-equity firms have shown interest. The $20 billion figure is a sources-say valuation for talks, not a signed purchase price.
This is a reported negotiation, not a definitive agreement or a closed exit. Mark the ~$20 billion talk level, the $9.3 billion 2025 revenue print, the multi-firm interest line, and the spin-off alternative as sourced. Do not invent a signed SPA, an EBITDA multiple, or a close date. The allocator object is a mega-cap sponsor bid for a scale orthopedics franchise that J&J has already labeled for separation.